AD is a growing market with an impressive pipeline of new products from current and future players in the field.

Boehringer and Cue Biopharma have entered a strategic research partnership and licence agreement for the latter’s CUE-501.

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

BMS could soon face competition in the HCM space as Cytokinetics awaits a marketing application decision from the FDA for ...

One concern with in vivo CAR-Ts is the potential insertional mutagenesis of the lentiviral DNA payload, causing secondary cancers.

Coherus BioSciences has completed the sale of its Udenyca (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals for up to $558.4m.

At the ESCMID Global conference in Austria, the development of climate-informed infectious disease risk management systems was discussed.

Valneva has received marketing authorisation from the Brazilian Health Regulatory Agency for its single-dose chikungunya vaccine, Ixchiq.

Concerns over a potential US recession this year are growing as investors assess the impact of Trump's tariff policies.

The FDA will require an additional Phase III trial for apraglutide, the company's candidate for short bowel syndrome.

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

The latest trends in cell therapies indicate a growing confidence in their effectiveness, an expansion of applications beyond oncology and significant market growth potential. However, the industry ...